Envision Scientific: Company Profile, Owner, Products, Stents, PTCA Balloons and Latest Medical Device Developments
Introduction
Envision Scientific Private Limited is an Indian medical-device manufacturing company based in Surat, Gujarat, specializing in advanced cardiovascular and vascular drug-delivery technologies. The company is particularly known for manufacturing Drug-Eluting Stents (DES) and Drug-Coated Balloons (DCB) used in minimally invasive vascular procedures.
Envision Scientific is part of the Concept Medical Group and serves as the group’s manufacturing establishment for drug-delivery devices. Its manufacturing capabilities combine catheter technology, vascular-device engineering, drug coating, nanotechnology and controlled manufacturing processes.
The company has a particularly interesting position in India’s medical-device industry because it is not primarily a general hospital-equipment manufacturer. Instead, it concentrates on high-value interventional cardiovascular and peripheral vascular devices.
Envision Scientific Company Details
Company Detail Information Company Name Envision Scientific Private Limited Industry Medical Devices / Interventional Cardiology Main Specialization Drug-Eluting Stents and Drug-Coated Balloons Established / Incorporated 22 December 2008 Headquarters Surat, Gujarat, India Parent/Group Concept Medical Group Company Type Private Limited Company Major Manufacturing Location Surat, Gujarat Major Technologies DES, DCB, Sirolimus drug delivery, Nanolute and proprietary coating technologies Markets 60+ countries according to the current manufacturing profile Annual Manufacturing Capacity More than 1 million drug-delivery devices Major Clinical Areas Coronary, peripheral vascular, AV fistula/graft and selected vascular applications
The incorporation date of Envision Scientific Private Limited is recorded as 22 December 2008 in company-registration data. The company currently operates from Surat and lists its registered office in Nanpura, Surat, along with manufacturing facilities in Ichchhapore/Bhatpore and Surat SEZ.
Who Is the Owner of Envision Scientific?
Envision Scientific is a privately held company, so its ownership structure is different from a listed company where shareholding is easily visible to the public.
The company is part of the Concept Medical Group. Envision describes itself as the group’s manufacturing establishment, while Concept Medical is responsible for research, development and commercialization of advanced drug-delivery technologies.
Manish Doshi
Manish Doshi is the most prominent founder and entrepreneurial figure associated with the Concept Medical–Envision Scientific group.
Public company profiles identify Doshi as a Founder and CEO, while Concept Medical’s own material describes him as the key person connecting technology, research and market requirements.
Doshi’s background is notable because he is an engineer rather than a medical doctor. His career eventually moved into medical-device technology, where he became involved in the development of cardiovascular drug-delivery devices. A 2026 profile describes his development journey from engineering and industrial businesses into medtech entrepreneurship.
Directors / Promoters
Public company-registration information lists individuals including:
- Manish Indulal Doshi
- Bhavdip Doshi Indulal
- Ambrish Laxmidas Thakker
- Nipulkumar Himatbhai Patel
- Parth Manish Doshi
as directors associated with Envision Scientific Private Limited.
Because Envision is a private company, it is more accurate to describe Manish Doshi as the prominent founder/entrepreneur associated with the group rather than claiming that he personally owns 100% of Envision Scientific.
What Does Envision Scientific Manufacture?
Envision Scientific has a specialized portfolio rather than hundreds of unrelated hospital products.
Its current official product portfolio is centered around two major categories:
1. Drug-Eluting Stents (DES)
These are vascular stents that deliver a drug at the treated artery.
2. Drug-Coated Balloons (DCB)
These are angioplasty balloon catheters coated with a therapeutic drug, designed to deliver the drug to the vessel wall without leaving a permanent implant.
The company currently lists five named Drug-Eluting Stent products and four named Drug-Coated Balloon products on its main product page — at least nine publicly listed flagship product platforms. This should not be interpreted as nine total SKUs, because individual devices are available in multiple sizes, lengths and configurations.
Envision Scientific Product List
Drug-Eluting Stents
The current official portfolio lists:
- Abluminus DES+
- Abluminus NP
- Nostrum
- Fusion
- Mitigator
Drug-Coated Balloons
The current official portfolio lists:
- MagicTouch SCB
- MagicTouch PTA
- MagicTouch AVF
- MagicTouch ED
Therefore, the current public product page shows 9 major named product platforms.
However, the actual number of individual device configurations is considerably larger because catheter products are offered in different diameters, lengths and technical configurations.
1. Abluminus DES+
Abluminus DES+ is one of the company’s best-known coronary drug-eluting stent technologies.
It uses the company’s proprietary ENVISOLUTION technology and is designed for coronary artery disease. The company particularly highlights its application in challenging patient populations, including patients with diabetes and acute myocardial infarction.
The basic concept is straightforward:
Stent → placed in narrowed artery → drug released at treatment site → intended to reduce restenosis.
2. Abluminus NP
Abluminus NP is a polymer-free sirolimus-eluting stent system.
The technology uses abluminal and fusion coating approaches to deliver sirolimus toward the vessel wall.
Its design is intended to provide therapeutic drug delivery while supporting vascular healing.
3. Nostrum
Nostrum is a sirolimus-eluting stent with an abluminal biodegradable coating.
The objective is targeted drug delivery to the vessel wall while the stent provides mechanical support to the treated artery.
4. Fusion Peripheral Stent
Fusion is designed for peripheral vascular intervention.
The company describes it as being intended to prevent re-narrowing in the superficial femoral and popliteal arteries in patients with peripheral artery disease.
This means Envision’s portfolio is not limited to coronary arteries.
5. Mitigator
Mitigator is a sirolimus-eluting stent using a biodegradable polymer.
According to Envision’s product information, the polymer is designed to degrade over approximately six to seven months.
Drug-Coated Balloon Technology
One of Envision Scientific’s most important technologies is the Drug-Coated Balloon.
A DCB is different from a stent.
With a conventional stent:
Balloon opens artery → stent remains inside artery.
With a drug-coated balloon:
Balloon reaches narrowed area → balloon expands → drug transfers to vessel wall → balloon is removed.
Therefore, the balloon itself is not intended to remain permanently inside the vessel.
Envision’s DCB technology primarily uses sirolimus and proprietary drug-delivery technologies.
MagicTouch SCB
MagicTouch SCB is the company’s coronary sirolimus-coated balloon platform.
The company describes it as a sirolimus-coated balloon designed for coronary artery disease, including applications such as:
- De novo lesions
- In-stent restenosis
- Small vessels
- Bifurcation lesions
MagicTouch uses the company’s Nanolute drug-delivery technology.
Concept Medical states that MagicTouch was the world’s first commercially approved sirolimus-coated balloon for coronary use, receiving CE Mark approval in 2016.
MagicTouch PTA
MagicTouch PTA is designed for peripheral arterial disease.
The current product information includes applications involving:
- Superficial femoral artery
- Popliteal artery
- Below-the-knee arteries
- Iliac arteries
- De novo lesions
- Stenotic lesions
- In-stent restenosis
It uses the proprietary Nanolute platform for sirolimus delivery.
The company also reports U.S. FDA IDE approvals for BTK and SFA clinical indications. These IDE approvals permit clinical investigation; they should not be interpreted as unrestricted U.S. commercial approval.
MagicTouch AVF
MagicTouch AVF is designed for stenotic lesions affecting dysfunctional arteriovenous fistulas and grafts.
AV fistulas and grafts are important vascular-access routes for many haemodialysis patients.
This product therefore extends Envision’s drug-coated balloon technology into dialysis-access intervention.
MagicTouch ED
MagicTouch ED is a specialized sirolimus-coated balloon technology for selected cases of vasculogenic erectile dysfunction.
The company describes its intended application in lesions involving arteries such as the internal pudendal, dorsal or urethral arteries.
This is a specialized vascular application and should not be confused with conventional treatment for all forms of erectile dysfunction.
What Is PTCA Balloon Catheter?
PTCA stands for Percutaneous Transluminal Coronary Angioplasty.
A PTCA balloon catheter is a thin catheter with an inflatable balloon near its tip.
During angioplasty, a physician guides the catheter through the vascular system until the balloon reaches a narrowed coronary artery.
The balloon is then inflated to widen the narrowed section.
Depending on the patient’s anatomy and clinical situation, a stent may subsequently be placed, or a drug-coated balloon may be considered where clinically appropriate.
Envision Scientific is therefore involved in a segment of interventional cardiology where extremely small and technically precise devices are used.
How Many Products Does Envision Scientific Have?
This is an important point for a company article.
It would be misleading to write that Envision Scientific has only nine products.
The current official website publicly identifies nine major named product platforms:
DES — 5
- Abluminus DES+
- Abluminus NP
- Nostrum
- Fusion
- Mitigator
DCB — 4
- MagicTouch SCB
- MagicTouch PTA
- MagicTouch AVF
- MagicTouch ED
These platforms have multiple device sizes and configurations.
The company also states that its manufacturing facilities can produce more than one million drug-delivery devices annually.
So for a website article, the accurate statement is:
Envision Scientific currently lists nine major named DES and DCB product platforms on its public product portfolio, with multiple configurations, while its manufacturing infrastructure has capacity for more than one million drug-delivery devices annually.
Where Does Envision Scientific Sell Its Products?
Envision Scientific states that its manufacturing operation supplies advanced drug-delivery products to more than 60 countries.
The wider Concept Medical Group currently describes a commercial presence in 80+ countries, so the manufacturing company’s 60+ country figure and the group’s 80+ country commercial figure should not be mixed together.
Its international markets include major healthcare regions such as:
- Europe
- Asia
- Latin America
- Japan
- Middle Eastern markets
- Other international markets
The company specifically states that its quality systems support markets including the United States, Japan and Europe.
Product approval and availability vary by country.
Envision Scientific Manufacturing Facilities
The company currently lists two major manufacturing locations in Surat:
Manufacturing Unit I
Ichchhapore GIDC Industrial Estate, Bhatpore, Surat, Gujarat
Manufacturing Unit II
Surat Special Economic Zone (SurSEZ), Sachin, Surat, Gujarat
These facilities support production of advanced drug-delivery medical devices.
Cleanroom Manufacturing
Manufacturing vascular implants and drug-coated catheter products requires tightly controlled production environments.
Envision Scientific states that its facilities include ISO Class 5 / Class 100 cleanrooms.
Its manufacturing systems monitor environmental parameters such as:
- Temperature
- Relative humidity
- Differential pressure
- Contamination levels
The company also reports in-process quality-control checks throughout production.
Quality Certifications
Envision Scientific reports a broad range of quality and management certifications.
Its current manufacturing information lists standards including:
- ISO 9001
- ISO 13485
- EN ISO 13485
- ISO 14001
- ISO 41001
- ISO/IEC 27001
- ISO 22301
- ISO/IEC 17025
- ISO 45001
The company also describes regulatory compliance systems supporting markets such as the US FDA, PMDA Japan, ANVISA Brazil, EU MDR and CDSCO India.
Research and Development
Research and development is an important part of Envision Scientific’s business.
The company’s technologies combine:
- Medical-device engineering
- Drug delivery
- Nanotechnology
- Coating technology
- Catheter design
- Biomaterials
- Manufacturing engineering
- Clinical research
The company describes its use of proprietary processes, equipment and machinery for manufacturing DES and DCB devices.
The wider Concept Medical group is responsible for much of the research, clinical development and commercialization activity associated with these technologies.
Nanolute Technology
Nanolute is one of the key technologies associated with the MagicTouch family.
It is designed to deliver very small particles of sirolimus to vascular tissue.
The company describes Nanolute as a proprietary sub-micron drug-delivery platform that uses a phospholipid carrier and specialized coating technology.
The technology is intended to improve drug transfer and retention while allowing the balloon catheter to be removed after treatment.
Envision Scientific and Concept Medical: What Is the Difference?
This is another important point for a company article.
Concept Medical
Concept Medical focuses heavily on:
- Research
- Product development
- Clinical programmes
- Commercialization
- Global market development
- Drug-delivery technology
Envision Scientific
Envision Scientific is the group’s major manufacturing establishment for these drug-delivery devices.
The company itself describes Envision as the manufacturing establishment of Concept Medical.
Therefore, the two names should not automatically be treated as two completely unrelated medical-device companies.
Latest Medical Device Developments
MagicTouch SCB Expands U.S. Clinical Development
One of the most important recent developments is the continued clinical development of MagicTouch SCB in the United States.
In August 2025, Concept Medical announced the first patient enrollment in the MAGICAL-SV U.S. IDE trial, studying MagicTouch SCB for small coronary vessels.
This is a clinical-development milestone rather than a new commercial product launch.
Latest Peripheral Vascular Development: MAGICAL BTK
Another important recent development is the MAGICAL BTK U.S. IDE pivotal trial for MagicTouch PTA.
The trial is studying the sirolimus-coated balloon against standard balloon angioplasty for below-the-knee arterial disease.
The first patient was enrolled as part of the company’s effort to expand the peripheral arterial disease clinical programme in the United States.
Again, this should be described as a clinical-development milestone, not as a newly launched machine or unrestricted U.S. commercial product.
2025 Brazil Commercial Approval for MagicTouch SCB
In September 2025, Concept Medical announced that Brazil’s health regulator ANVISA granted commercial approval for MagicTouch SCB for coronary artery disease treatment.
The company described this as the first and only ANVISA-approved sirolimus-coated balloon for CAD in Brazil at that time.
This is an example of the group’s continuing international expansion.
Latest 2026 Development
A March 2026 company publication highlighted the continued development of MagicTouch and described plans to expand its use into additional vascular applications.
The same report stated that the group’s technologies are commercially available in more than 80 countries, while U.S. commercial launch of MagicTouch was projected for 2028. It also described ongoing development in areas including below-the-knee vascular disease and other specialized vascular indications.
Therefore, as of 2026, the most accurate way to describe the company’s “new launches” is that Envision/Concept Medical is expanding and clinically developing the existing MagicTouch and other drug-delivery platforms into new indications and markets, rather than claiming that a completely new machine was launched in 2026.
Patents and Innovation
Innovation and intellectual property are major parts of the Concept Medical–Envision story.
A 2025 profile reported that the companies had developed drug-coated stent and balloon technologies supported by approximately 30 international patents at that stage.
A 2026 profile from the group later reported that 132 patents had been granted globally across its broader technology portfolio. Because these figures refer to different dates and potentially different scopes of the group’s intellectual-property portfolio, they should not be presented as the exact number of patents owned solely by Envision Scientific.
Manufacturing Capacity
One of the most significant numbers for Envision Scientific is its production capacity.
The company states that its manufacturing infrastructure has the capacity to produce more than one million drug-delivery devices annually.
This is particularly significant because cardiovascular stents and drug-coated balloons require highly controlled manufacturing, coating and quality-testing processes.
What Diseases and Procedures Are These Devices Used For?
Envision Scientific’s products are designed for interventional treatment areas including:
Coronary Artery Disease
Coronary stents and coronary drug-coated balloons can be used in selected coronary interventions.
Peripheral Artery Disease
Peripheral drug-coated balloons and stents are used in selected peripheral vascular interventions.
In-Stent Restenosis
Certain MagicTouch and DES technologies are designed for selected restenotic lesions.
Small-Vessel Disease
MagicTouch SCB is being clinically studied for small-vessel coronary disease.
Dialysis Access
MagicTouch AVF is designed for selected stenotic lesions in dialysis-related fistulas and grafts.
Vasculogenic Erectile Dysfunction
MagicTouch ED is designed for selected arterial lesions associated with vasculogenic erectile dysfunction.
Why Envision Scientific Is Important for India
India has historically relied significantly on imported high-end medical devices.
Companies such as Envision Scientific represent India’s move toward domestic manufacturing of sophisticated interventional devices.
The company combines:
Indian manufacturing + cardiovascular engineering + drug delivery + nanotechnology + clinical research + international commercialization.
This makes it different from conventional Indian manufacturers focused primarily on syringes, gloves, hospital furniture or basic consumables.
Employment and Company Size
Public company profiles place Envision Scientific in the small-to-medium private medical-device-company category, although employee counts vary between public sources and may not reflect the wider Concept Medical Group.
For website publication, it is therefore safer to focus on its manufacturing capacity and global footprint rather than publish an unverified current employee number.
The company currently describes itself as having a dedicated workforce supporting manufacturing, quality and advanced drug-delivery production.
Future of Envision Scientific
The company’s future growth is closely linked to the expansion of drug-coated balloon therapy and advanced drug-eluting technologies.
Its development areas include:
- Coronary artery disease
- Small-vessel coronary disease
- In-stent restenosis
- Peripheral artery disease
- Below-the-knee disease
- Dialysis vascular access
- Other specialized vascular indications
The company is also expanding regulatory and clinical programmes in international markets.
The broader Concept Medical Group currently reports more than 45 clinical trial programmes and an evidence base involving more than 24,000 patients, although these figures refer to the wider group and should not be treated as Envision Scientific-only clinical data.
Envision Scientific vs Conventional Medical Equipment Companies
Envision Scientific is quite different from companies such as BPL Medical Technologies or Allengers Medical Systems. Company Main Area Allengers Medical Systems X-ray, radiology, C-arms, mammography and imaging BPL Medical Technologies ECG, patient monitoring, critical care, imaging and hospital equipment Trivitron Healthcare Diagnostics, imaging, critical care and laboratory equipment Envision Scientific Drug-eluting stents, drug-coated balloons and vascular drug delivery
Envision therefore belongs more specifically to the interventional cardiovascular and vascular-device sector.
Frequently Asked Questions
When was Envision Scientific established?
Envision Scientific Private Limited was incorporated on 22 December 2008, according to company-registration information.
Who is the founder of Envision Scientific?
Manish Doshi is the key founder and entrepreneur associated with the Concept Medical–Envision Scientific group and is publicly identified as a founder and CEO.
Who owns Envision Scientific?
Envision Scientific is a private company and forms part of the Concept Medical Group. Its exact private shareholding should not be simplified into a claim that one individual owns the entire company.
Where is Envision Scientific headquartered?
The company is based in Surat, Gujarat, India. Its head office is currently listed at Trinity Orion, Vesu, Surat.
What does Envision Scientific manufacture?
Its main manufacturing focus is Drug-Eluting Stents (DES) and Drug-Coated Balloons (DCB) for cardiovascular and peripheral vascular applications.
How many major products does Envision Scientific have?
The current official product page lists five DES platforms and four DCB platforms, making at least nine named major product platforms publicly listed. Individual platforms have multiple sizes and configurations.
What is the annual manufacturing capacity?
The company states that it can manufacture more than one million drug-delivery devices annually.
In how many countries are its products sold?
Envision Scientific’s current manufacturing page states that it caters to more than 60 countries. The wider Concept Medical Group reports a commercial presence in 80+ countries.
What is the most famous Envision Scientific product?
The MagicTouch family of sirolimus-coated balloons is among the group’s most prominent technologies, particularly MagicTouch SCB for coronary intervention.
Does Envision Scientific manufacture X-ray or MRI machines?
No. Envision Scientific is not primarily an imaging-equipment manufacturer. Its core business is interventional vascular drug-delivery devices, especially DES and DCB products.
Does Envision Scientific manufacture stents?
Yes. Its portfolio includes multiple Drug-Eluting Stent platforms, including Abluminus DES+, Abluminus NP, Nostrum, Fusion and Mitigator.
Does Envision Scientific manufacture balloon catheters?
Yes. Its portfolio includes several drug-coated balloon catheter systems, including MagicTouch SCB, MagicTouch PTA, MagicTouch AVF and MagicTouch ED.
What is the latest major development?
Recent developments include continued U.S. clinical programmes for MagicTouch SCB and MagicTouch PTA, including the MAGICAL-SV and MAGICAL BTK studies, along with international regulatory expansion such as the 2025 commercial approval of MagicTouch SCB in Brazil.
Conclusion
Envision Scientific is one of India’s more specialized medical-device manufacturers, with a business model focused on advanced cardiovascular and vascular drug-delivery technologies rather than general hospital equipment.
Established in 2008 and headquartered in Surat, the company operates as the manufacturing arm of the Concept Medical Group and specializes in Drug-Eluting Stents and Drug-Coated Balloons.
Its current public product portfolio includes major platforms such as Abluminus DES+, Abluminus NP, Nostrum, Fusion, Mitigator, MagicTouch SCB, MagicTouch PTA, MagicTouch AVF and MagicTouch ED.
The company states that its manufacturing facilities can produce more than one million drug-delivery devices annually and serve 60+ countries.
Its development of sirolimus-coated balloon technology, particularly the MagicTouch platform, is one of the most significant aspects of its technology portfolio. Recent clinical trials and international regulatory developments show that the company is continuing to expand these technologies into new vascular indications and markets.
For India’s medical-device industry, Envision Scientific is significant because it demonstrates that Indian companies can participate not only in basic medical consumables but also in complex implantable devices, interventional cardiology, drug delivery, nanotechnology and advanced vascular therapies.
Note: Medical-device indications, approvals and availability differ by country and product version. Product information should always be checked against the applicable regulatory approval and Instructions for Use before clinical use.
